Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 614

1.

The Evolving Concept of a Therapeutic Community.

Aaronson ST, Mouratidis M.

Psychiatry. 2019 Mar 14:1-3. doi: 10.1080/00332747.2019.1565557. [Epub ahead of print] No abstract available.

PMID:
30870112
2.

Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression.

Kumar A, Bunker MT, Aaronson ST, Conway CR, Rothschild AJ, Mordenti G, Rush AJ.

Neuropsychiatr Dis Treat. 2019 Feb 13;15:457-468. doi: 10.2147/NDT.S196665. eCollection 2019.

3.

SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.

Ahmed TA, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson SA, Poulikakos PI.

Cell Rep. 2019 Jan 2;26(1):65-78.e5. doi: 10.1016/j.celrep.2018.12.013.

4.

Kinesin-2 and IFT-A act as a complex promoting nuclear localization of β-catenin during Wnt signalling.

Vuong LT, Iomini C, Balmer S, Esposito D, Aaronson SA, Mlodzik M.

Nat Commun. 2018 Dec 13;9(1):5304. doi: 10.1038/s41467-018-07605-z.

5.

Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive.

Rush AJ, Aaronson ST, Demyttenaere K.

Aust N Z J Psychiatry. 2019 Feb;53(2):109-118. doi: 10.1177/0004867418808585. Epub 2018 Oct 31.

PMID:
30378447
6.

Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Chen HM, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, Alsina-Beauchamp D, Duty JA, Mungamuri SK, Zhang B, Moran T, Flavell R, Aaronson S, Hu HM, Arase H, Ramanathan S, Flores R, Pan PY, Chen SH.

J Clin Invest. 2018 Dec 3;128(12):5647-5662. doi: 10.1172/JCI97570. Epub 2018 Oct 22.

7.

Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial.

Martin DM, McClintock SM, Aaronson ST, Alonzo A, Husain MM, Lisanby SH, McDonald WM, Mohan A, Nikolin S, O'Reardon J, Weickert CS, Loo CK.

Brain Stimul. 2018 Nov - Dec;11(6):1282-1290. doi: 10.1016/j.brs.2018.08.011. Epub 2018 Aug 23.

PMID:
30172724
8.

Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression.

Conway CR, Kumar A, Xiong W, Bunker M, Aaronson ST, Rush AJ.

J Clin Psychiatry. 2018 Aug 21;79(5). pii: 18m12178. doi: 10.4088/JCP.18m12178.

9.

Neuromodulation.

Aaronson ST, Philip NS.

Psychiatr Clin North Am. 2018 Sep;41(3):xiii-xvi. doi: 10.1016/j.psc.2018.06.001. Epub 2018 Jul 17. No abstract available.

PMID:
30098663
10.

Vagus Nerve Stimulation: Changing the Paradigm for Chronic Severe Depression?

Aaronson ST, Conway CR.

Psychiatr Clin North Am. 2018 Sep;41(3):409-418. doi: 10.1016/j.psc.2018.05.001. Review.

PMID:
30098654
11.

Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B.

van der Touw W, Kang K, Luan Y, Ma G, Mai S, Qin L, Bian G, Zhang R, Mungamuri SK, Hu HM, Zhang CC, Aaronson SA, Feldmann M, Yang WC, Chen SH, Pan PY.

J Immunol. 2018 Sep 15;201(6):1727-1734. doi: 10.4049/jimmunol.1701450. Epub 2018 Aug 1.

PMID:
30068593
12.

Neurocognitive Effects of Repetitive Transcranial Magnetic Stimulation With a 2-Coil Device in Treatment-Resistant Major Depressive Disorder.

Kavanaugh BC, Aaronson ST, Clarke GN, Holtzheimer PE, Johnson CW, McDonald WM, Schneider MB, Carpenter LL.

J ECT. 2018 Dec;34(4):258-265. doi: 10.1097/YCT.0000000000000494.

PMID:
29613944
13.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

14.

International randomized-controlled trial of transcranial Direct Current Stimulation in depression.

Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM, McClintock SM, Mohan A, Lisanby SH; International Consortium of Research in tDCS (ICRT).

Brain Stimul. 2018 Jan - Feb;11(1):125-133. doi: 10.1016/j.brs.2017.10.011. Epub 2017 Oct 27.

PMID:
29111077
15.

Extracellular LDLR repeats modulate Wnt signaling activity by promoting LRP6 receptor endocytosis mediated by the Itch E3 ubiquitin ligase.

Vijayakumar S, Liu G, Wen HC, Abu Y, Chong R, Nastri H, Bornstein GG, Pan ZQ, Aaronson SA.

Genes Cancer. 2017 Jul;8(7-8):613-627. doi: 10.18632/genesandcancer.146.

16.

Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.

Koola MM, Sklar J, Davis W, Nikiforuk A, Meissen JK, Sawant-Basak A, Aaronson ST, Kozak R.

Schizophr Res. 2018 Mar;193:459-460. doi: 10.1016/j.schres.2017.07.005. Epub 2017 Jul 11. No abstract available.

PMID:
28705532
17.

rTMS with a two-coil array: Safety and efficacy for treatment resistant major depressive disorder.

Carpenter LL, Aaronson ST, Clarke GN, Holtzheimer PE, Johnson CW, McDonald WM, Stannard EL, Schneider MB.

Brain Stimul. 2017 Sep - Oct;10(5):926-933. doi: 10.1016/j.brs.2017.06.003. Epub 2017 Jun 9.

PMID:
28642024
18.

p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.

Pappas K, Xu J, Zairis S, Resnick-Silverman L, Abate F, Steinbach N, Ozturk S, Saal LH, Su T, Cheung P, Schmidt H, Aaronson S, Hibshoosh H, Manfredi J, Rabadan R, Parsons R.

Mol Cancer Res. 2017 Aug;15(8):1051-1062. doi: 10.1158/1541-7786.MCR-17-0089. Epub 2017 May 8.

19.

DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation.

Kim HG, Hwang SY, Aaronson SA, Mandinova A, Lee SW.

J Biol Chem. 2017 Apr 28;292(17):7162. doi: 10.1074/jbc.A111.236612. No abstract available.

20.

A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality.

Aaronson ST, Sears P, Ruvuna F, Bunker M, Conway CR, Dougherty DD, Reimherr FW, Schwartz TL, Zajecka JM.

Am J Psychiatry. 2017 Jul 1;174(7):640-648. doi: 10.1176/appi.ajp.2017.16010034. Epub 2017 Mar 31. Erratum in: Am J Psychiatry. 2017 Sep 1;174(9):907.

PMID:
28359201
21.

Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging.

Fay F, Hansen L, Hectors SJCG, Sanchez-Gaytan BL, Zhao Y, Tang J, Munitz J, Alaarg A, Braza MS, Gianella A, Aaronson SA, Reiner T, Kjems J, Langer R, Hoeben FJM, Janssen HM, Calcagno C, Strijkers GJ, Fayad ZA, Pérez-Medina C, Mulder WJM.

Bioconjug Chem. 2017 May 17;28(5):1413-1421. doi: 10.1021/acs.bioconjchem.7b00086. Epub 2017 May 5.

22.

Modeling intratumor heterogeneity through CRISPR-barcodes.

Guernet A, Aaronson SA, Anouar Y, Grumolato L.

Mol Cell Oncol. 2016 Sep 6;3(6):e1227894. doi: 10.1080/23723556.2016.1227894. eCollection 2016.

23.

Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW.

Nat Rev Immunol. 2016 Dec;16(12):741-750. doi: 10.1038/nri.2016.99. Epub 2016 Sep 26. Review.

24.

Study design and methodology for a multicentre, randomised controlled trial of transcranial direct current stimulation as a treatment for unipolar and bipolar depression.

Alonzo A, Aaronson S, Bikson M, Husain M, Lisanby S, Martin D, McClintock SM, McDonald WM, O'Reardon J, Esmailpoor Z, Loo C.

Contemp Clin Trials. 2016 Nov;51:65-71. doi: 10.1016/j.cct.2016.10.002. Epub 2016 Oct 15.

PMID:
27756567
25.

RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress.

Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto GP, Kim YB, Aaronson SA, Lee SW.

Curr Biol. 2016 Aug 22;26(16):2221-2222. doi: 10.1016/j.cub.2016.07.072. No abstract available.

26.

Synthetic recombinase-based state machines in living cells.

Roquet N, Soleimany AP, Ferris AC, Aaronson S, Lu TK.

Science. 2016 Jul 22;353(6297):aad8559. doi: 10.1126/science.aad8559. Epub 2016 Jul 21.

27.

CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.

Guernet A, Mungamuri SK, Cartier D, Sachidanandam R, Jayaprakash A, Adriouch S, Vezain M, Charbonnier F, Rohkin G, Coutant S, Yao S, Ainani H, Alexandre D, Tournier I, Boyer O, Aaronson SA, Anouar Y, Grumolato L.

Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.

28.

Erratum to "Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study" [Brain Stimulation 9 (2016) 251-257].

Philip NS, Dunner DL, Dowd SM, Aaronson ST, Brock DG, Carpenter LL, Demitrack MA, Hovav S, Janicak PG, George MS.

Brain Stimul. 2016 Jul-Aug;9(4):639. doi: 10.1016/j.brs.2016.03.015. Epub 2016 Mar 29. No abstract available.

PMID:
27320180
29.

Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations.

Troilo A, Benson EK, Esposito D, Garibsingh RA, Reddy EP, Mungamuri SK, Aaronson SA.

Oncotarget. 2016 May 17;7(20):28765-82. doi: 10.18632/oncotarget.9117.

30.

USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation.

Mungamuri SK, Qiao RF, Yao S, Manfredi JJ, Gu W, Aaronson SA.

Cell Rep. 2016 Mar 22;14(11):2528-37. doi: 10.1016/j.celrep.2016.02.049. Epub 2016 Mar 10.

31.

Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study.

Philip NS, Dunner DL, Dowd SM, Aaronson ST, Brock DG, Carpenter LL, Demitrack MA, Hovav S, Janicak PG, George MS.

Brain Stimul. 2016 Mar-Apr;9(2):251-7. doi: 10.1016/j.brs.2015.11.007. Epub 2015 Nov 25.

32.

Sustained Benefit Over Four-Year Follow-Up of Michigan's Project Healthy Schools.

Corriveau N, Eagle T, Jiang Q, Rogers R, Gurm R, Aaronson S, Mitchell L, DuRussel-Weston J, Kline-Rogers E, Eagle KA, Jackson EA.

Am J Public Health. 2015 Dec;105(12):e19-25. doi: 10.2105/AJPH.2015.302835. Epub 2015 Oct 15.

33.

Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.

Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS.

Brain Stimul. 2015 Jul-Aug;8(4):787-94. doi: 10.1016/j.brs.2015.05.005. Epub 2015 May 22.

PMID:
26143022
34.

Stable heteroplasmy at the single-cell level is facilitated by intercellular exchange of mtDNA.

Jayaprakash AD, Benson EK, Gone S, Liang R, Shim J, Lambertini L, Toloue MM, Wigler M, Aaronson SA, Sachidanandam R.

Nucleic Acids Res. 2015 Feb 27;43(4):2177-87. doi: 10.1093/nar/gkv052. Epub 2015 Feb 4.

35.

Cdo suppresses canonical Wnt signalling via interaction with Lrp6 thereby promoting neuronal differentiation.

Jeong MH, Ho SM, Vuong TA, Jo SB, Liu G, Aaronson SA, Leem YE, Kang JS.

Nat Commun. 2014 Nov 19;5:5455. doi: 10.1038/ncomms6455.

36.

Scaffold hopping approach on the route to selective tankyrase inhibitors.

Liscio P, Carotti A, Asciutti S, Ferri M, Pires MM, Valloscuro S, Ziff J, Clark NR, Macchiarulo A, Aaronson SA, Pellicciari R, Camaioni E.

Eur J Med Chem. 2014 Nov 24;87:611-23. doi: 10.1016/j.ejmech.2014.10.007. Epub 2014 Oct 5.

37.

A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period.

Dunner DL, Aaronson ST, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, Brock DG, Bonneh-Barkay D, Cook IA, Lanocha K, Solvason HB, Demitrack MA.

J Clin Psychiatry. 2014 Dec;75(12):1394-401. doi: 10.4088/JCP.13m08977.

38.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19. Review.

39.

Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters.

Mungamuri SK, Wang S, Manfredi JJ, Gu W, Aaronson SA.

Oncogene. 2015 May 7;34(19):2461-70. doi: 10.1038/onc.2014.198. Epub 2014 Jul 14.

40.

Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.

Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, Dickerson FB.

Schizophr Res. 2014 Aug;157(1-3):84-9. doi: 10.1016/j.schres.2014.04.037. Epub 2014 May 28. Review.

41.

Brachyury: a new player in promoting breast cancer aggressiveness.

Pires MM, Aaronson SA.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju094. doi: 10.1093/jnci/dju094. No abstract available.

PMID:
24815862
42.

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors.

Liscio P, Carotti A, Asciutti S, Karlberg T, Bellocchi D, Llacuna L, Macchiarulo A, Aaronson SA, Schüler H, Pellicciari R, Camaioni E.

J Med Chem. 2014 Mar 27;57(6):2807-12. doi: 10.1021/jm401356t. Epub 2014 Feb 24.

43.

High-density lipoprotein cholesterol levels in middle-school children: association with cardiovascular risk factors and lifestyle behaviors.

Flynn SE, Gurm R, DuRussel-Weston J, Aaronson S, Gakenheimer L, Smolarski J, Simhaee D, Corriveau N, Goldberg C, Eagle T, Rao RM, Eagle KA, Jackson EA.

Pediatr Cardiol. 2014 Mar;35(3):507-13. doi: 10.1007/s00246-013-0814-1. Epub 2013 Oct 17.

PMID:
24132620
44.

Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.

Mungamuri SK, Murk W, Grumolato L, Bernstein E, Aaronson SA.

Cell Rep. 2013 Oct 31;5(2):302-13. doi: 10.1016/j.celrep.2013.09.009. Epub 2013 Oct 10.

45.

p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes.

Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ, Aaronson SA.

Oncogene. 2014 Jul 24;33(30):3959-69. doi: 10.1038/onc.2013.378. Epub 2013 Oct 7.

46.

The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo.

Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M, Manfredi JJ.

Genes Dev. 2013 Sep 1;27(17):1868-85. doi: 10.1101/gad.224386.113.

47.

β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors.

Grumolato L, Liu G, Haremaki T, Mungamuri SK, Mong P, Akiri G, Lopez-Bergami P, Arita A, Anouar Y, Mlodzik M, Ronai ZA, Brody J, Weinstein DC, Aaronson SA.

PLoS Genet. 2013;9(8):e1003603. doi: 10.1371/journal.pgen.1003603. Epub 2013 Aug 15.

48.

A middle school intervention to improve health behaviors and reduce cardiac risk factors.

Eagle TF, Gurm R, Smith CA, Corriveau N, DuRussell-Weston J, Palma-Davis L, Aaronson S, Goldberg C, Kline-Rogers E, Cotts T, Jackson EA, Eagle KA.

Am J Med. 2013 Oct;126(10):903-8. doi: 10.1016/j.amjmed.2013.04.019. Epub 2013 Aug 8.

PMID:
23932159
49.

Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice.

Janicak PG, Dunner DL, Aaronson ST, Carpenter LL, Boyadjis TA, Brock DG, Cook IA, Lanocha K, Solvason HB, Bonneh-Barkay D, Demitrack MA.

CNS Spectr. 2013 Dec;18(6):322-32. doi: 10.1017/S1092852913000357. Epub 2013 Jul 30.

PMID:
23895940
50.

Wnk kinases are positive regulators of canonical Wnt/β-catenin signalling.

Serysheva E, Berhane H, Grumolato L, Demir K, Balmer S, Bodak M, Boutros M, Aaronson S, Mlodzik M, Jenny A.

EMBO Rep. 2013 Aug;14(8):718-25. doi: 10.1038/embor.2013.88. Epub 2013 Jun 25. Erratum in: EMBO Rep. 2013 Sep;14(9):845.

Supplemental Content

Loading ...
Support Center